Capital Nasdaq Biotechnology Etf Current Ratio
| 00678 Etf | TWD 29.34 0.54 1.81% |
Capital Nasdaq Biotechnology fundamentals help investors to digest information that contributes to Capital Nasdaq's financial success or failures. It also enables traders to predict the movement of Capital Etf. The fundamental analysis module provides a way to measure Capital Nasdaq's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Capital Nasdaq etf.
Capital |
Capital Nasdaq Biotechnology ETF Current Ratio Analysis
Capital Nasdaq's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Capital Nasdaq Biotechnology has a Current Ratio of 0.0 times. This indicator is about the same for the Capital Investment Trust Co., Ltd average (which is currently at 0.0) family and about the same as Current Ratio (which currently averages 0.0) category. This indicator is about the same for all Taiwan etfs average (which is currently at 0.0).
Capital Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Capital Nasdaq's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of Capital Nasdaq could also be used in its relative valuation, which is a method of valuing Capital Nasdaq by comparing valuation metrics of similar companies.Capital Nasdaq is currently under evaluation in current ratio as compared to similar ETFs.
Fund Asset Allocation for Capital Nasdaq
The fund consists of 98.58% investments in stocks, with the rest of investments allocated between various types of exotic instruments.Asset allocation divides Capital Nasdaq's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
Capital Fundamentals
| Total Asset | 178.4 M | |||
| One Year Return | 27.30 % | |||
| Three Year Return | 8.82 % | |||
| Net Asset | 178.4 M | |||
| Equity Positions Weight | 98.58 % |
About Capital Nasdaq Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Capital Nasdaq Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Capital Nasdaq using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Capital Nasdaq Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Capital Etf
Capital Nasdaq financial ratios help investors to determine whether Capital Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Capital with respect to the benefits of owning Capital Nasdaq security.